Oppenheimer raised the firm’s price target on TransMedics to $125 from $105 and keeps an Outperform rating on the shares. The firm cites the company’s Q1 beat and raised FY24 guidance.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX: